ACT, CO and MO biomodulation protocols based on REAC® Technology at Lipedema World Congress 2025

Lipedema represents one of the most complex challenges in modern medicine: a chronic condition characterized by symmetric accumulation of adipose tissue, often associated with chronic pain, edema, inflammation, circulatory dysfunction and metabolic alterations. In this context, the Lipedema World Congress it confirms itself as an international reference event for the scientific and clinical community, bringing together lymphologists, angiologists, plastic surgeons, physiatrists, nutritionists and specialists in regenerative medicine to share the latest advances in diagnostic, pathophysiological and therapeutic fields.

Among the companies present, REAC Technology – produced exclusively by ASMED® Srl – contributes to the field of non-invasive biomodulation. At their stand, visitors have the opportunity to learn more about the specific REAC® protocols designed to act on the key mechanisms of lipedema:

• ACT (Anti-inflammatory Anticellulite): aimed at reducing systemic and localised inflammation, improving microcirculation, lymphatic drainage and skin elasticity.

• CO (Circulation Optimization): It optimises blood flow, reduces edema and promotes lymphatic drainage, relieving the feeling of heaviness in the limbs.

• MO (Metabolic Optimization): Supports the restoration of cellular metabolic balance, improving energy efficiency and contributing to the management of often associated insulin resistance.

REAC® protocols are based on the use of low-intensity asymmetric radio fields that modulate endogenous bioelectric activity, promoting cellular and tissue repair processes. The inventors of the technology, Prof. Salvatore Rinaldi and Dr. Vania Fontani of the Rinaldi Fontani Institute, are present to illustrate the mechanisms of action and share the clinical experience gained.

The approach is supported by peer-reviewed publications indexed in PubMed (authors Rinaldi and Fontani), which document the effectiveness of REAC® in reducing chronic pain, oedema and improving circulatory and metabolic parameters in lipedema-related conditions, including rheumatoid arthritis, fibromyalgia and postmenopausal lipodystrophy.

In a therapeutic landscape that still sees limited effective and safe conservative options, REAC® Technology is proposed as a complementary tool, easily integrated into multidisciplinary paths, non-invasive and well tolerated.

For physicians interested in deepening scientific rationale and clinical applications, they can deepen the published studies on PubMed and the website of thethe Rinaldi Fontani Institute.